923 related articles for article (PubMed ID: 29786183)
21. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.
Chernin G; Gal-Oz A; Ben-Assa E; Schwartz IF; Weinstein T; Schwartz D; Silverberg DS
Clin Cardiol; 2012 Jan; 35(1):32-6. PubMed ID: 22057933
[TBL] [Abstract][Full Text] [Related]
22. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Hyperkalemia in Heart Failure.
DeFilippis EM; Desai AS
Curr Heart Fail Rep; 2017 Aug; 14(4):266-274. PubMed ID: 28656517
[TBL] [Abstract][Full Text] [Related]
24. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
25. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
Hoorn EJ
Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
[TBL] [Abstract][Full Text] [Related]
26. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
[TBL] [Abstract][Full Text] [Related]
28. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.
Gruver J; Al-Makki A; Shepler B
J Pharm Pharm Sci; 2023; 26():11892. PubMed ID: 38173862
[TBL] [Abstract][Full Text] [Related]
30. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
31. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.
Mohamed Pakkir Maideen N; Balasubramanian R; Muthusamy S; Nallasamy V
Curr Cardiol Rev; 2022; 18(6):e110522204611. PubMed ID: 35546745
[TBL] [Abstract][Full Text] [Related]
32. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
33. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
Rafique Z; Peacock WF; LoVecchio F; Levy PD
Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
[TBL] [Abstract][Full Text] [Related]
34. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
Oktaviono YH; Kusumawardhani N
Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
[TBL] [Abstract][Full Text] [Related]
35. Potassium binding for conservative and preservative management of chronic kidney disease.
Clegg DJ; Palmer BF
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
[TBL] [Abstract][Full Text] [Related]
36. New therapies for hyperkalemia.
Leon SJ; Harasemiw O; Tangri N
Curr Opin Nephrol Hypertens; 2019 May; 28(3):238-244. PubMed ID: 30865167
[TBL] [Abstract][Full Text] [Related]
37. Potential New Agents for the Management of Hyperkalemia.
Packham DK; Kosiborod M
Am J Cardiovasc Drugs; 2016 Feb; 16(1):19-31. PubMed ID: 26156040
[TBL] [Abstract][Full Text] [Related]
38. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
Lazich I; Bakris GL
Semin Nephrol; 2014 May; 34(3):333-9. PubMed ID: 25016403
[TBL] [Abstract][Full Text] [Related]
39. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
[TBL] [Abstract][Full Text] [Related]
40. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
